title: Gene signatures in breast cancer: current and future uses.
abstract: Gene signatures have been developed for estrogen receptor-positive breast cancer to complement pathological factors in providing prognostic information. The 70-gene and the 21-gene signatures identify patients who may not require adjuvant chemotherapy. Gene signatures in triple-negative disease and HER2-positive disease have not been fully developed yet, although studies demonstrate heterogeneity within these subgroups. Further research is needed before genotyping will help in making clinical decisions in triple-negative and HER2-positive disease. Molecular subtyping of breast cancer led to define luminal, basal, and HER2-enriched subtypes, which have specific clinical behavior. This approach may lead to identify new subgroups requiring specific therapies. Standardization of techniques will be required to translate investigations to the clinic.
authors: Servicio de Oncología Médica, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain.
authors: Enrique Espinosa
authors: EE
authors: Arranz
authors: Juan Ángel Fresno
authors: JÁ
authors: Vara
authors: Angelo
authors: A
authors: Gámez-Pozo
authors: Pilar
authors: P
authors: Zamora